Alize Pharma, a Lyon, France-based group of companies developing drugs for the treatment of metabolic diseases and cancer, has completed a €3.3m funding round.
Backers include existing shareholders Sham, OCTALFA, CEMA Inc., and Thierry Abribat.
The company intends to use this capital, which brings the total amount raised to date to €8.3m, to take AZP-531, its UAG (UnAcylated Ghrelin) analog for the treatment of the Prader Willi syndrome and type II diabetes, into Phase I clinical trials.
Led by president & CEO Thierry Abribat, Alize Pharma is comprised of two entities:
– Alize Pharma SAS, which is dedicated to a peptide (AZP-531) derived from unacylated ghrelin, currently at the preclinical stage of development for the treatment of the Prader Willi Syndrome and Type II diabetes.
– Alize Pharma II SAS, which is focused on the development of ASPAREC(R), a new PEGylated recombinant L-asparaginase for the treatment of acute lymphoblastic leukemia, partnered with EUSA Pharma and currently in Phase I clinical development.